GILEAD | Medical Information

Bixlenvo™ (bictegravir/lenacapavir) Pharmacokinetics

This document is in response to your request for information regarding Bixlenvo™ (bictegravir/lenacapavir [BIC/LEN]) and its pharmacokinetics (PK).

Some data may be outside of the US FDA-approved prescribing information. In providing this data, Gilead Sciences, Inc. is not making any representation as to its clinical relevance or to the use of any Gilead product(s). For information about the approved conditions of use of any Gilead drug product, please consult the FDA-approved prescribing information.

The full indication, important safety information, and boxed warnings are available at: www.gilead.com/-/media/files/pdfs/medicines/hiv/BIXLENVO/BIXLENVO_pi; www.gilead.com/-/media/files/pdfs/medicines/hiv/SUNLENCA/SUNLENCA_pi.

Summary

Product Labeling[1]

BIC/LEN is indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current ARV regimen in those who are VS (HIV-1 RNA <50 c/mL) on a stable ARV regimen with no known or suspected resistance to the individual components of BIC/LEN.

The PK properties of BIC/LEN are provided in Table 1. The PK parameter estimates of the components of BIC/LEN following administration of the recommended BIC/LEN treatment regimen with or without food in adults with HIV-1 are provided in Table 2.

Clinical Data on the PK of BIC/LEN

The PK of BIC and LEN were assessed using data from ARTISTRY-1 and ARTISTRY-2, two phase 3 studies that are evaluating the efficacy and safety of BIC/LEN in VS PWH. With intensive PK sampling in ARTISTRY-1, the observed mean steady-state C_{trough} concentrations at dosing at up to 8 hours post-dose were approximately 26- to 30-fold above the IQ1 of 162 ng/mL for BIC and approximately 21- to 29-fold above the IQ1 of 3.87 ng/mL for LEN. In ARTISTRY-1 and ARTISTRY-2, plasma C_{trough} BIC and LEN concentrations were above the IQ1 at Weeks 24, 36, and 48.[2]

Product Labeling[1]

Indications and Use

BIC/LEN is indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current ARV regimen in those who are VS (HIV-1 RNA <50 c/mL) on a stable ARV regimen with no known or suspected resistance to the individual components of BIC/LEN.

Dosage and Administration

Recommended dosage

The BIC/LEN dosing schedule in adults requires a two-day initiation regimen of BIC/LEN tablets plus LEN tablets taken orally, followed by a maintenance regimen of one tablet of BIC/LEN taken orally once daily. BIC/LEN must be taken with LEN during the two-day initiation period. BIC/LEN and LEN tablets may be taken with or without food.

Clinical Pharmacology

PK

The PK properties of BIC/LEN are provided in Table 1. The PK parameter estimates of the components of BIC/LEN following administration of the recommended BIC/LEN treatment regimen with or without food in adults with HIV-1 are provided in Table 2.

Table 1. PK Properties of the Components of BIC/LEN[1]

Parameter			BIC	LEN
Absorption	T_{max},[a] hours		2	4
	Effect of high-fat meal (relative to fasting)[b]	AUC ratio	1.12 (1.01, 1.25)	0.67 (0.53, 0.83)
		C_{max} ratio	1.16 (1.07, 1.26)	0.86 (0.67, 1.09)
Distribution	% bound to human plasma proteins		>99	>98.5
	Blood-to-plasma ratio		0.64[c]	0.5 to 0.7[d]
Elimination	$T_{1/2}$[a]		19.3 to 21 hours	10.6 to 11.5 days
Metabolism	Metabolic pathway(s)		CYP3A UGT1A1 (minor)	
Excretion	Major route of elimination		Metabolism	Excretion of unchanged drug into feces
	% of dose excreted in urine[e]		35	<1
	% of dose excreted in feces[e]		60.3	76

Abbreviations: ^{14}C=carbon-14; AUC=area under the concentration-time curve; $T_{1/2}$=elimination half-life; T_{max}=time required to reach maximum plasma concentration; UGT1A1=uridine diphosphate glucuronosyl transferase family 1 member A1.
[a]Median values presented following administration of BIC/LEN with or without food.
[b]Values refer to geometric mean ratio (high-fat meal/fasting) in PK parameters and (90% CI). A high-fat meal is approximately 800 kcal, 50% fat.
[c]In vitro blood-to-plasma concentration ratio of BIC.
[d]Values reflect the blood-to-plasma ratio of LEN following a single dose of IV administration of ^{14}C LEN through 336 hours postdose.
[e]Dosing in mass balance studies: single dose oral administration of ^{14}C BIC 100 mg, and single dose IV administration of ^{14}C LEN 20 mg.

Table 2. PK Parameter Estimates[a] of BIC and LEN Following Oral Administration of the BIC/LEN Recommended Treatment Regimen With or Without Food in Adults With HIV-1[1]

Parameter, Mean (%CV)	Initiation Regimen[a,b]	Maintenance Regimen[c]	
	LEN	BIC	LEN
C_{max}, ng/mL	95.7 (186)	8600 (29)	99.3 (171)
AUC_{τ}, ng*h/mL	2080 (182)	154,000 (33.3)	2360 (178)
C_{trough},ng/mL	86.5 (185)	4660 (39.8)	96.6 (174)

[a]Empirical Bayes estimate derived PK parameters from population PK analyses.
[b]Exposures corresponding to Day 2 of the recommended treatment regimen (N=806).
[c]Steady-state exposures from population PK analyses in ARTISTRY-1 and ARTISTRY-2 (N=754).

Clinical Data on the PK of BIC/LEN

ARTISTRY-1 and ARTISTRY-2: Phase 3 Studies

Study designs and demographics

ARTISTRY-1 is an ongoing, randomized, multicenter, open-label, phase 2/3 study (NCT05502341) that is evaluating the efficacy and safety of switching to BIC/LEN vs continuing their ART regimen in PWH who were receiving a complex ART regimen.[3,4]

ARTISTRY-2 is an ongoing, randomized, multicenter, double-blind, active-controlled, phase 3 study (NCT06333808) that is evaluating the efficacy and safety of switching from BIC/FTC/TAF to STR BIC/LEN 75 mg/50 mg vs continuing BIC/FTC/TAF in VS PWH. After the randomized period, participants could continue in the open-label extension phase and receive BIC/LEN.[5]

An analysis was conducted to describe the PK of BIC and LEN to support the observed safety and efficacy of BIC/LEN in the ARTISTRY studies. In both studies, sparse PK blood samples were collected pre- and/or post-dose from participants in the BIC/LEN groups at specified weekly intervals from baseline through Week 48 (Figure 1). In addition, intensive PK sampling was conducted in a subset of participants in the BIC/LEN group of ARTISTRY-1 at a steady-state visit at Week 24, 36, or 48 (Figure 1). Concentrations of BIC and LEN were determined using bioanalytical assays.[2]

Figure 1. ARTISTRY-1 and ARTISTRY-2: Study Designs and PK Sampling[2]



Abbreviations: NNRTI=non-nucleos(t)ide reverse transcriptase inhibitor; NRTI=nucleos(t)ide reverse transcriptase inhibitor; PI=protease inhibitor.
[a]Participants were on a complex ART regimen due to ARV resistance, intolerance, drug-drug interactions, or contraindications to existing STRs. A complex multi-tablet regimen was defined as a regimen that contained any of the following: a boosted PI or NNRTI plus ≥1 other third agent from a class other than NRTI, or ≥2 pills/day, or requiring dosing more than daily, or parenteral agent(s) (excluding a complete long-acting injectable regimen) as well as oral agents.
[b]BIC/LEN 75/50 mg, with oral loading dose of LEN 600 mg on Days 1 and 2 of treatment.
[c]Participants were given placebo to match oral LEN on Days 1 and 2 of treatment.

Table 3. ARTISTRY-1 and ARTISTRY-2: Baseline Demographics and Disease Characteristics of BIC/LEN Participants With Sparse PK Data

Key Demographics and Characteristics	ARTISTRY-1 (n=371)	ARTISTRY-2 (n=383)
Age, median (Q1, Q3), years	60 (55, 66)	47 (38, 58)
Male sex at birth, %	82.7	82
Body weight, median (Q1, Q3), kg	79.6 (68.7, 90)	81.1 (71.8, 92.8)

Key Demographics and Characteristics	ARTISTRY-1 (n=371)	ARTISTRY-2 (n=383)
BMI, median (Q1, Q3), kg/m^2	26.1 (23.1, 29.9)	26.8 (24.2, 30.3)
$CrCl_{CG}$, median (Q1, Q3), mL/min	82.9 (66.4, 103.2)	101.4 (83.9, 117)
Prior ARV medications, median (Q1, Q3), n	7 (3, 14)	Not available

Abbreviations: CG=Cockcroft-Gault; Q=quartile.

PK data[2]

The observed mean steady-state C_{trough} concentrations at dosing and at all assessed time points thereafter were approximately 26- to 30-fold above the IQ1 of 162 ng/mL for BIC and approximately 21- to 29-fold above the IQ1 of 3.87 ng/mL for LEN (Figure 2).

Figure 2. ARTISTRY-1: BIC and LEN Concentration-Time Profiles[2]



Abbreviation: LLOQ=lower level of quantitation.
Note: Intensive serial PK sampling collection was performed at Week 24, 36, or 48. Mean concentration values that were ≤LLOQ are not shown in the figure.

The steady-state BIC and LEN PK data from ARTISTRY-1 and ARTISTRY-2 are presented in Table 4.

Table 4. ARTISTRY-1 and ARTISTRY-2: Steady-State PK Data for BIC and LEN[2]

Parameter				C_{trough}, Mean (%CV), ng/mL	C_{max}, Mean (%CV), ng/mL	AUC_T, Mean (%CV), h*ng/mL
BIC	ARTISTRY-1	Intensive PK		4190 (52.6), n=89	8670 (35), n=97	140,000 (40.6), n=89
		Sparse PK	W24	4480 (55.4), n=264	-	-
			W36	4400 (53.4), n=292	-	-
			W48	4290 (49.6), n=211	-	-
	ARTISTRY-2	Sparse PK	W24	4880 (53.7), n=314	-	-
			W36	4630 (53.4), n=305	-	-
			W48	4760 (50.4), n=191	-	-

Parameter				C_{trough}, Mean (%CV), ng/mL	C_{max}, Mean (%CV), ng/mL	AUC_T, Mean (%CV), h*ng/mL
LEN	ARTISTRY-1	Intensive PK		81.5 (70.8), n=51	107 (76.2), n=97	2130 (69.2), n=51
		Sparse PK	W24	103 (104), n=267	-	-
			W36	113 (109), n=293	-	-
			W48	106 (100), n=213	-	-
	ARTISTRY-2	Sparse PK	W24	94.8 (109), n=313	-	-
			W36	89.2 (86.5), n=305	-	-
			W48	94.8 (106), n=225	-	-

Note: PK data snapshots were taken on 19-September-2025 for ARTISTRY-1 and 17-October-2025 for ARTISTRY-2. BIC/LEN was administered with an oral loading dose of LEN 600 mg on Days 1 and 2. Intensive PK data were analyzed using standard non-compartmental analysis.

Plasma C_{trough} BIC and LEN concentrations from ARTISTRY-1 and ARTISTRY-2 were above each respective IQ1 at all assessed time points (Figure 3).

Figure 3. ARTISTRY-2 Plasma BIC and LEN C_{trough} Concentrations[2]



References

1. Enclosed, Gilead Sciences Inc. BIXLENVO™ (bictegravir and lenacapavir) tablets, for oral use. U.S. Prescribing Information. Foster City, CA.
2. Arora P, Guo Y, Wen A, Montezuma-Rusca JM, Sklar P, Marathe DD. Pharmacokinetic Data Supporting the Safety and Efficacy of BIC/LEN in Phase 3 Studies [Poster TUPEB094]. Paper presented at: The 26th International AIDS Conference (AIDS); July 26–31, 2026; Rio de Janeiro, Brazil.
3. Mounzer K, Slim J, Ramgopal M, et al. Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline. *Open Forum Infectious Diseases.* 2025;12(11):ofaf615.

4. Mounzer K, Slim J, Ramgopal M, et al. Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex HIV Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1). *Clin Infect Dis.* 2025;80(4):881-888.
5. Meissner EG, Ramgopal M, Ruane PJ, et al. Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial. *Lancet HIV.* 2026;(8):e538-e547.

Abbreviations

ART=antiretroviral therapy
ARV=antiretroviral
AUC_T=area under the concentration-time curve over the dosing interval
BIC=bictegravir
c/mL=copies/mL
C_{max}=maximum observed drug concentration
C_{trough}=lowest observed drug concentration
CV=coefficient of variation
FTC=emtricitabine
IQ1=inhibitory quotient 1
LEN=lenacapavir
PK=pharmacokinetic(s)
PWH=people with HIV-1
STR=single-tablet regimen
VS=virologically suppressed

Product Label

For the full indication, important safety information, and boxed warning(s), please refer to the Bixlenvo and Sunlenca US Prescribing Information available at: www.gilead.com/-/media/files/pdfs/medicines/hiv/BIXLENVO/BIXLENVO_pi; www.gilead.com/-/media/files/pdfs/medicines/hiv/SUNLENCA/SUNLENCA_pi.

Follow-Up

For any additional questions, please contact Gilead Medical Information at:

☎1-866-MEDI-GSI (1-866-633-4474) or 🖱 www.askgileadmedical.com

Adverse Event Reporting

Please report all adverse events to:

Gilead Global Patient Safety ☎ 1-800-445-3235, option 3 or
🖱 www.gilead.com/utility/contact/report-an-adverse-event

FDA MedWatch Program by ☎ 1-800-FDA-1088 or ✉MedWatch, FDA, 5600 Fishers Ln, Rockville, MD 20852 or 🖱 www.accessdata.fda.gov/scripts/medwatch

Data Privacy

The Medical Information service at Gilead Sciences may collect, store, and use your personal information to provide a response to your medical request. We may share your information with other Gilead Sciences colleagues to ensure that your request is addressed appropriately. If you report an adverse event or concern about the quality of a Gilead or Kite product, we will need to use the information you have given us in order to meet our regulatory requirements in relation to the safety of our medicines.

It may be necessary for us to share your information with Gilead's affiliates, business partners, service providers, and regulatory authorities located in countries besides your own. Gilead Sciences has implemented measures to protect the personal information you provide. Please see the Gilead Privacy Statement (www.gilead.com/privacy-statements) for more information about how Gilead handles your personal information and your rights. If you have any further questions about the use of your personal information, please contact gilead.privacy@gilead.com.